Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cyclo Therapeutics Inc
CYTH | US
0.81
USD0.04
4.65%
CYTH | US
About Cyclo Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.81
Open
0.80
High
0.81
Low
0.78
Cyclo Therapeutics Inc. a clinical stage biotechnology company develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo an orphan drug which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition it sells cyclodextrins and related products to the pharmaceutical nutritional and other industries primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings Inc. and changed its name to Cyclo Therapeutics Inc. in September 2019. Cyclo Therapeutics Inc. was incorporated in 1990 and is based in Gainesville Florida.
View LessCYTH | US
Risk
56.1
Sharpe
-0.35
Luna's Score
46/100
Recommendation
Hold
Luna says (CYTH | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
44.3%1 month
56.1%3 months
84.2%6 months
76.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
59.10
Debt to equity
-0.59
Debt to assets
0.64
Ent. to EBITDA
-0.47
Ent. to rev.
21.55
PEG
-
Other Fundamentals
EBITDA
-21.14M
MarketCap
23.24M
MarketCap(USD)
23.24M
Div. yield
-
Op. margin
-4.58K
Erngs. growth
-
Rev. growth
5.10
Ret. on equity
-22.66K
Short ratio
3.25
Short perc.
0.68
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.10
Range1M
0.15
Range3M
0.75
Volumes: Market Activity
Rel. volume
0.97
Price X volume
26.23K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.47 | - | Cheaper |
| Ent. to Revenue | 21.55 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 59.10 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 84.19 | - | Par |
| Debt to Equity | -0.59 | -1.23 | Expensive |
| Debt to Assets | 0.64 | 0.25 | Expensive |
| Market Cap | 23.24M | - | Emerging |
